|
1
|
Dasari S, Wudayagiri R and Valluru L:
Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim
Acta. 445:7–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arbyn M, Castellsagué X, de Sanjosé S,
Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of
cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosch FX and de Sanjosé S: Chapter 1:
Human papillomavirus and cervical cancer - burden and assessment of
causality. J Natl Cancer Inst Monogr. 2003:3–13. 2003. View Article : Google Scholar
|
|
5
|
Yu Y, Zhang Y and Zhang S: MicroRNA-92
regulates cervical tumorigenesis and its expression is upregulated
by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett.
6:468–474. 2013.PubMed/NCBI
|
|
6
|
Yee GP, de Souza P and Khachigian LM:
Current and potential treatments for cervical cancer. Curr Cancer
Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dizon DS, Mackay HJ, Thomas GM, Werner TL,
Kohn EC, Hess D, Rose PG and Covens AL: State of the science in
cervical cancer: Where we are today and where we need to go.
Cancer. 120:2282–2288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Du J, Wang L, Li C, Yang H, Li Y, Hu H, Li
H and Zhang Z: MicroRNA-221 targets PTEN to reduce the sensitivity
of cervical cancer cells to gefitinib through the PI3K/Akt
signaling pathway. Tumour Biol. 37:3939–3947. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Q, Han LR, Zhou YX and Li Y: MiR-195
suppresses cervical cancer migration and invasion through targeting
Smad3. Int J Gynecol Cancer. 26:817–824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X and Xia Y: microRNA-328 inhibits
cervical cancer cell proliferation and tumorigenesis by targeting
TCF7L2. Biochem Biophys Res Commun. 475:169–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai S, Lu Y, Long Y, Lai Y, Du P, Ding N
and Yao D: Prognostic value of microRNAs in cervical carcinoma: A
systematic review and meta-analysis. Oncotarget. 7:35369–35378.
2016.PubMed/NCBI
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aigner A: MicroRNAs (miRNAs) in cancer
invasion and metastasis: Therapeutic approaches based on
metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
22
|
Zheng L, Jiao W, Mei H, Song H, Li D,
Xiang X, Chen Y, Yang F, Li H, Huang K, et al: miRNA-337-3p
inhibits gastric cancer progression through repressing myeloid zinc
finger 1-facilitated expression of matrix metalloproteinase 14.
Oncotarget. 7:40314–40328. 2016.PubMed/NCBI
|
|
23
|
Gao M, Liu L, Li S, Zhang X, Chang Z and
Zhang M: Inhibition of cell proliferation and metastasis of human
hepatocellular carcinoma by miR-137 is regulated by CDC42. Oncol
Rep. 34:2523–2532. 2015.PubMed/NCBI
|
|
24
|
Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X,
Jin X and Tian X: MicroRNA-183 functions as the tumor suppressor
via inhibiting cellular invasion and metastasis by targeting MMP-9
in cervical cancer. Gynecol Oncol. 141:166–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Hu L, Tian C, Lu F, Wu J and Liu L:
microRNA-150 promotes cervical cancer cell growth and survival by
targeting FOXO4. BMC Mol Biol. 16:242015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song X, Shi B, Huang K and Zhang W:
miR-133a inhibits cervical cancer growth by targeting EGFR. Oncol
Rep. 34:1573–1580. 2015.PubMed/NCBI
|
|
27
|
Deng B, Zhang Y, Zhang S, Wen F, Miao Y
and Guo K: MicroRNA-142-3p inhibits cell proliferation and invasion
of cervical cancer cells by targeting FZD7. Tumour Biol.
36:8065–8073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng W, Liu Z, Zhang W and Hu X: miR-31
functions as an oncogene in cervical cancer. Arch Gynecol Obstet.
292:1083–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ni F, Gui Z, Guo Q, Hu Z, Wang X, Chen D
and Wang S: Downregulation of miR-362-5p inhibits proliferation,
migration and invasion of human breast cancer MCF7 cells. Oncol
Lett. 11:1155–1160. 2016.PubMed/NCBI
|
|
30
|
Yang P, Ni F, Deng RQ, Qiang G, Zhao H,
Yang MZ, Wang XY, Xu YZ, Chen L, Chen DL, et al: MiR-362-5p
promotes the malignancy of chronic myelocytic leukaemia via
down-regulation of GADD45α. Mol Cancer. 14:1902015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z,
Guo C, Liu Y, Chen Z, Wang X, et al: MicroRNA-362-5p promotes tumor
growth and metastasis by targeting CYLD in hepatocellular
carcinoma. Cancer Lett 356B. 809–818. 2015. View Article : Google Scholar
|
|
32
|
Xia JT, Chen LZ, Jian WH, Wang KB, Yang
YZ, He WL, He YL, Chen D and Li W: MicroRNA-362 induces cell
proliferation and apoptosis resistance in gastric cancer by
activation of NF-κB signaling. J Transl Med. 12:332014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu K, Yang L, Chen J, Zhao H, Wang J, Xu S
and Huang Z: miR-362-5p inhibits proliferation and migration of
neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β.
FEBS Lett. 589:1911–1919. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Behbakht K, Qamar L, Aldridge CS, Coletta
RD, Davidson SA, Thorburn A and Ford HL: Six1 overexpression in
ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and
is associated with poor survival. Cancer Res. 67:3036–3042. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Tian T, Hu X, Zhang X, Nan F, Chang
Y, Lv F and Zhang M: Six1 mediates resistance to paclitaxel in
breast cancer cells. Biochem Biophys Res Commun. 441:538–543. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kahlert C, Lerbs T, Pecqueux M, Herpel E,
Hoffmeister M, Jansen L, Brenner H, Chang-Claude J, Bläker H, Kloor
M, et al: Overexpression of SIX1 is an independent prognostic
marker in stage I–III colorectal cancer. Int J Cancer.
137:2104–2113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei Q, Yu WW, Zhao KL, Fu XL, Zhu ZF, Qin
GQ, Chen H, Zhang ZX, Gu YZ, Xiang JQ, et al: Expression of Six1
and Six4 in esophageal squamous cell carcinoma and their
correlation with clinical prognosis. Zhonghua Bing Li Xue Za Zhi.
42:446–450. 2013.(In Chinese). PubMed/NCBI
|
|
38
|
Li Z, Tian T, Lv F, Chang Y, Wang X, Zhang
L, Li X, Li L, Ma W, Wu J, et al: Six1 promotes proliferation of
pancreatic cancer cells via upregulation of cyclin D1 expression.
PLoS One. 8:e592032013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan J, Zhang C and Qian J: Expression and
significance of Six1 and Ezrin in cervical cancer tissue. Tumour
Biol. 32:1241–1247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng XH, Liang PH, Guo JX, Zheng YR, Han
J, Yu LL, Zhou YG and Li L: Expression and clinical implications of
homeobox gene Six1 in cervical cancer cell lines and cervical
epithelial tissues. Int J Gynecol Cancer. 20:1587–1592.
2010.PubMed/NCBI
|
|
41
|
Wang CA, Jedlicka P, Patrick AN, Micalizzi
DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC and Ford HL:
SIX1 induces lymphangiogenesis and metastasis via upregulation of
VEGF-C in mouse models of breast cancer. J Clin Invest.
122:1895–1906. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ono H, Imoto I, Kozaki K, Tsuda H, Matsui
T, Kurasawa Y, Muramatsu T, Sugihara K and Inazawa J: SIX1 promotes
epithelial-mesenchymal transition in colorectal cancer through ZEB1
activation. Oncogene. 31:4923–4934. 2012. View Article : Google Scholar : PubMed/NCBI
|
